1. Oikonomou N，Harokopos V，Zalevsky J，et al.Soluble TNF mediates the transition from pulmonary inflammation to fibrosis.PLoS One，2006，1：e108.

2. Meneghin A，Hogaboam C M.Infectious disease，the innate immune response，and fibrosis.J Clin Invest，2007，117（3）：530-538.

3. Wynn T A.Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.J Clin Invest，2007，117 （3）：524-529.

4. Speca S，Giusti I，Rieder F，et al. Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol，2012，18（28）：3635-3661.

5. Wynn T A，Ramalingam T R.Mechanisms of fibrosis：therapeutic translation for fibrotic disease.Nat Med，2012，18（7）：1028-1040.

6. Rosenbloom J，Mendoza F A，Jimenez S A.Strategies for antifibrotic therapies.Biochim Biophys Acta，2012.

7. Serhan C N，Savill J.Resolution of inflammation：the beginning programs the end. Nat Immunol，2005，6（12）：1191-1197.

8. Ariel A，Chiang N，Arita M，et al.Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-αlpha secretion from human T cells.J Immunol，2003，170（12）：6266-6272.

9. Godson C，Mitchell S，Harvey K，et al.Cutting edge：lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages.J Immunol，2000，164（4）：1663-1667.

10. Soyombo O，Spur B W，Lee T H.Effects of lipoxin A4 on chemotaxis and degranulation of human eosinophils stimulated by platelet-activating factor and N-formyl-L-methionyl-L-leucyl-L-phenylalanine.Allergy，1994，49（4）：230-234.

11. Hachicha M，Pouliot M，Petasis N A，et al.Lipoxin（LX）A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking：regulators of a cytokine-chemokine axis.J Exp Med，1999，189（12）：1923-1930.

12. Ramstedt U，Serhan C N，Nicolaou K C，et al.Lipoxin A-induced inhibition of human natural killer cell cytotoxicity：studies on stereospecificity of inhibition and mode of action. J Immunol，1987，138（1）：266-270.

13. Serhan C N.Resolution phase of inflammation：novel endogenous anti-inflammatory and proresolving lipid mediators and pathways.Annu Rev Immunol，2007，25：101-137.

14. Haworth O，Levy B D.Endogenous lipid mediators in the resolution of airway inflammation. Eur Respir J，2007，30 （5）：980-992.

15. Cattaneo F，Parisi M，Ammendola R.Distinct signaling cascades elicited by different formyl Peptide receptor 2 （FPR2）agonists.Int J Mol Sci，2013，14（4）：7193-7230.

16. Serhan C N.Lipoxins and aspirin-triggered 15-epi-lipoxins are the first lipid mediators of endogenous anti-inflammation and resolution.Prostaglandins Leukot Essent Fatty Acids，2005，73（3-4）：141-162.

17. Levy B D.Lipoxins and lipoxin analogs in asthma.Prostaglandins Leukot Essent Fatty Acids，2005，73（3-4）：231-237.

18. Fiore S，Serhan C N.Formation of lipoxins and leukotrienes during receptor-mediated interactions of human platelets and recombinant human granulocyte/macrophage colonystimulating factor-primed neutrophils.J Exp Med，1990，172（5）：1451-1457.

19. Levy B D，Romano M，Chapman H A，et al.Human alveolar macrophages have 15-lipoxygenase and generate 15（S）-hydroxy-5，8，11-cis-13-trans-eicosatetraenoic acid and lipoxins.J Clin Invest，1993，92（3）：1572-1579.

20. Serhan C N，Hamberg M，Samuelsson B.Lipoxins：novel series of biologically active compounds formed from arachidonic acid in human leukocytes.Proc Natl Acad Sci USA，1984，81（17）：5335-5339.

21. Serhan C N，Sheppard K A.Lipoxin formation during human neutrophil-platelet interactions.Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro.J Clin Invest，1990，85（3）：772-780.

22. Claria J，Serhan C N.Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions.Proc Natl Acad Sci U S A，1995，92（21）：9475-9479.

23. Chiang N，Fierro I M，Gronert K，et al.Activation of lipoxin A（4）receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation.J Exp Med，2000，191（7）：1197-1208.

24. Gronert K，Gewirtz A，Madara J L，et al.Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin（IL）-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J Exp Med，1998，187（8）：1285-1294.

25. McMahon B，Godson C.Lipoxins：endogenous regulators of inflammation.Am J Physiol Renal Physiol，2004，286（2）：F189-F201.

26. Clish C B，Levy B D，Chiang N，et al.Oxidoreductases in lipoxin A4 metabolic inactivation：a novel role for 15-onoprostaglandin 13-reductase/leukotriene B4 12-hydroxydehydrogenase in inflammation.J Biol Chem，2000，275（33）：25372-25380.

27. Schottelius A J，Giesen C，Asadullah K，et al.An aspirintriggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile.J Immunol，2002，169（12）：7063-7070.

28. Jin H，Li Y H，Xu J S，et al.Lipoxin A4 analog attenuates morphine antinociceptive tolerance，withdrawal-induced hyperalgesia，and glial reaction and cytokine expression in the spinal cord of rat.Neuroscience，2012，208：1-10.

29. Serhan C N，Takano T，Clish C B，et al.Aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogs inhibit neutrophil-mediated changes in vascular permeability. Adv Exp Med Biol，1999，469：287-293.

30. Maddox J F，Colgan S P，Clish C B，et al.Lipoxin B4 regulates human monocyte/neutrophil adherence and motility： design of stable lipoxin B4 analogs with increased biologic activity.FASEB J，1998，12（6）：487-494.

31. Clish C B，O’Brien J A，Gronert K，et al.Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo.Proc Natl Acad Sci U S A，1999，96（14）：8247-8252.

32. Serhan C N，Clish C B，Brannon J，et al.Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing.J Exp Med，2000，192（8）：1197-1204.

33. Hong S，Lu Y.Omega-3 fatty acid-derived resolvins and protectins in inflammation resolution and leukocyte functions：targeting novel lipid mediator pathways in mitigation of acute kidney injury.Front Immunol，2013，4：13.

34. Recchiuti A.Resolvin D1 and its GPCRs in resolution circuits of inflammation. Prostaglandins Other Lipid Mediat，2013.

35. El K D，Gjorstrup P，Filep J G.Resolvin E1 promotes phagocytosis-induced neutrophil apoptosis and accelerates resolution of pulmonary inflammation.Proc Natl Acad Sci U S A，2012，109（37）：14983-14988.

36. Arita M，Bianchini F，Aliberti J，et al.Stereochemical assignment，antiinflammatory properties，and receptor for the omega-3 lipid mediator resolvin E1.J Exp Med，2005，201 （5）：713-722.

37. Hong S，Gronert K，Devchand P R，et al.Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain，human blood，and glial cells. Autacoids in anti-inflammation.J Biol Chem，2003，278（17）：14677-14687.

38. Serhan C N，Gotlinger K，Hong S，et al.Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers：assignments of dihydroxy-containing docosatrienes.J Immunol，2006，176（3）：1848-1859.

39. Im D S.Omega-3 fatty acids in anti-inflammation（pro-resolution）and GPCRs.Prog Lipid Res，2012，51（3）：232-237.

40. Zhang X，Wang J M，Gong W H，et al.Differential regulation of chemokine gene expression by 15-deoxy-delta 12，14 prostaglandin J2.J Immunol，2001，166（12）：7104-7111.

41. Herlong J L，Scott T R.Positioning prostanoids of the D and J series in the immunopathogenic scheme. Immunol Lett，2006，102（2）：121-131.

42. Takai D，Nagase T，Shimizu T.New therapeutic key for cystic fibrosis：a role for lipoxins.Nat Immunol，2004，5（4）：357-358.

43. Yang J，Eiserich J P，Cross C E，et al.Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients.Free Radic Biol Med，2012，53（1）：160-171.

44. Karp C L，Flick L M，Park K W，et al.Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.Nat Immunol，2004，5（4）：388-392.

45. Mattoscio D，Evangelista V，De Cristofaro R，et al.Cystic fibrosis transmembrane conductance regulator（CFTR）expression in human platelets：impact on mediators and mechanisms of the inflammatory response. FASEB J，2010，24 （10）：3970-3980.

46. Karp C L，Flick L M，Yang R，et al.Cystic fibrosis and lipoxins.Prostaglandins Leukot Essent Fatty Acids，2005，73 （3-4）：263-270.

47. Rozsasi A，Heinemann A，Keck T.Cyclooxygenase 2 and lipoxin A（4）in nasal polyps in cystic fibrosis.Am J Rhinol Allergy，2011，25（6）：e251-e254.

48. Kowal-Bielecka O，Kowal K，Distler O，et al.Mechanisms of Disease：leukotrienes and lipoxins in scleroderma lung disease--insights and potential therapeutic implications. Nat Clin Pract Rheumatol，2007，3（1）：43-51.

49. Silver R M，Wells A U.Histopathology and bronchoalveolar lavage.Rheumatology（Oxford），2008，47 Suppl 5：v62-v64.

50. Kowal-Bielecka O，Kowal K，Distler O，et al.Cyclooxygenase-and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease：an imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum，2005，52 （12）：3783-3791.

51. Lee E，Lee E J，Kim H，et al.Overexpression of apolipoprotein A1 in the lung abrogates fibrosis in experimental silicosis.PLoS One，2013，8（2）：e55827.

52. Tetaert D，Pierre M，Demeyer D，et al. Dietary n-3 fatty acids have suppressive effects on mucin upregulation in mice infected with Pseudomonas aeruginosa. Respir Res，2007，8：39.

53. Andersson C，Zaman M M，Jones A B，et al.Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages.J Cyst Fibros，2008，7（1）：68-78.

54. Qu X，Zhang X，Yao J，et al.Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation.J Pathol，2012.

55. Duffield J S，Hong S，Vaidya V S，et al.Resolvin D series and protectin D1 mitigate acute kidney injury.J Immunol，2006，177（9）：5902-5911.

56. Kieran N E，Maderna P，Godson C.Lipoxins：potential antiinflammatory，proresolution，and antifibrotic mediators in renal disease.Kidney Int，2004，65（4）：1145-1154.

57. Brennan E P，Nolan K A，Borgeson E，et al.Lipoxins Attenuate Renal Fibrosis by Inducing let-7c and Suppressing TGFbetaR1.J Am Soc Nephrol，2013，24（4）：627-637.

58. Borgeson E，Docherty N G，Murphy M，et al.Lipoxin A（4）and benzo-lipoxin A（4）attenuate experimental renal fibrosis.FASEB J，2011，25（9）：2967-2979.

59. Sato Y，Kitasato H，Murakami Y，et al.Down-regulation of lipoxin A4 receptor by thromboxane A2 signaling in RAW246.7 cells in vitro and bleomycin-induced lung fibrosis in vivo.Biomed Pharmacother，2004，58（6-7）：381-387.

60. Martins V，Valenca S S，Farias-Filho F A，et al.ATLa，an aspirin-triggered lipoxin A4 synthetic analog，prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis.J Immunol，2009，182（9）：5374-5381.

61. Klingberg F，Hinz B，White E S.The myofibroblast matrix：implications for tissue repair and fibrosis.J Pathol，2013，229（2）：298-309.

62. Hu B，Phan S H. Myofibroblasts. Curr Opin Rheumatol，2013，25（1）：71-77.

63. Hutchison N，Fligny C，Duffield J S.Resident mesenchymal cells and fibrosis.Biochim Biophys Acta，2012.

64. Lekkerkerker A N，Aarbiou J，van Es T，et al.Cellular players in lung fibrosis.Curr Pharm Des，2012，18（27）：4093-4102.

65. Mitchell D，Rodgers K，Hanly J，et al.Lipoxins inhibit Akt/ PKB activation and cell cycle progression in human mesangial cells.Am J Pathol，2004，164（3）：937-946.

66. McMahon B，Mitchell D，Shattock R，et al.Lipoxin，leukotriene，and PDGF receptors cross-talk to regulate mesangial cell proliferation.FASEB J，2002，16（13）：1817-1819.

67. Rodgers K，McMahon B，Mitchell D，et al.Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells. Am J Pathol，2005，167（3）：683-694.

68. Wu S H，Wu X H，Lu C，et al.Lipoxin A4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor.Am J Respir Cell Mol Biol，2006，34（1）：65-72.

69. Sodin-Semri S，Spagnolo A，Barbaro B，et al. Lipoxin A4 counteracts synergistic activation of human fibroblast-like synoviocytes.Int J Immunopathol Pharmacol，2004，17（1）：15-25.

70. Kronke G，Reich N，Scholtysek C，et al.The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis.Ann Rheum Dis，2012，71（6）：1081-1087.

71. Wu S H，Lu C，Dong L，et al.High dose of lipoxin A4 induces apoptosis in rat renal interstitial fibroblasts. Prostaglandins Leukot Essent Fatty Acids，2005，73（2）：127-137.

72. Iwano M，Plieth D，Danoff T M，et al.Evidence that fibroblasts derive from epithelium during tissue fibrosis.J Clin Invest，2002，110（3）：341-350.

73. Wu S H，Zhang Y M，Tao H X，et al.Lipoxin A（4）inhibits transition of epithelial to mesenchymal cells in proximal tubules.Am J Nephrol，2010，32（2）：122-136.

74. Nakerakanti S，Trojanowska M.The Role of TGF-beta Receptors in Fibrosis.Open Rheumatol J，2012，6：156-162.

75. Gordon K J，Blobe G C.Role of transforming growth factorbeta superfamily signaling pathways in human disease.Biochim Biophys Acta，2008，1782（4）：197-228.

76. Khan R，Sheppard R.Fibrosis in heart disease：understanding the role of transforming growth factor-beta in cardiomyopathy，valvular disease and arrhythmia.Immunology，2006，118（1）：10-24.

77. Coker R K，Laurent G J，Jeffery P K，et al.Localisation of transforming growth factor beta1 and beta3 mRNA transcripts in normal and fibrotic human lung.Thorax，2001，56 （7）：549-556.

78. Kitani A，Fuss I，Nakamura K，et al.Transforming growth factor（TGF）-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J Exp Med，2003，198（8）：1179-1188.

79. Verrecchia F，Mauviel A. Transforming growth factor-beta and fibrosis. World J Gastroenterol，2007，13（22）：3056-3062.

80. Brennan E P，Nolan K A，Borgeson E，et al.Lipoxins Attenuate Renal Fibrosis by Inducing let-7c and Suppressing TGFbetaR1.J Am Soc Nephrol，2013，24（4）：627-637.

81. Rieder F，Brenmoehl J，Leeb S，et al.Wound healing and fibrosis in intestinal disease.Gut，2007，56（1）：130-139.

82. Wynn T A.Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.J Clin Invest，2007，117（3）：524-529.

83. Speca S，Giusti I，Rieder F，et al. Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol，2012，18（28）：3635-3661.

84. Ueha S，Shand F H，Matsushima K.Cellular and molecular mechanisms of chronic inflammation-associated organ fibrosis.Front Immunol，2012，3：71.

85. Nathan C，Ding A.Nonresolving inflammation.Cell，2010，140（6）：871-882.

86. Serhan C N，Chiang N，Van Dyke T E.Resolving inflammation：dual anti-inflammatory and pro-resolution lipid mediators.Nat Rev Immunol，2008，8（5）：349-361.

87. Mangino M J，Brounts L，Harms B，et al.Lipoxin biosynthesis in inflammatory bowel disease.Prostaglandins Other Lipid Mediat，2006，79（1-2）：84-92.

88. Rozsasi A，Heinemann A，Keck T.Cyclooxygenase 2 and lipoxin A（4）in nasal polyps in cystic fibrosis.Am J Rhinol Allergy，2011，25（6）：e251-e254.

89. Borgeson E，McGillicuddy F C，Harford K A，et al.Lipoxin A4 attenuates adipose inflammation. FASEB J，2012，26 （10）：4287-4294.

90. Amalinei C，Caruntu I D，Giusca S E，et al.Matrix metalloproteinases involvement in pathologic conditions. Rom J Morphol Embryol，2010，51（2）：215-228.

91. Sweet D G，Curley A E，Chesshyre E，et al.The role of matrix metalloproteinases-9 and-2 in development of neonatal chronic lung disease.Acta Paediatr，2004，93（6）：791-796.

92. Zucker S，Vacirca J. Role of matrix metalloproteinases （MMPs）in colorectal cancer. Cancer Metastasis Rev，2004，23（1-2）：101-117.

93. Lopez B，Gonzalez A，Diez J.Role of matrix metalloproteinases in hypertension-associated cardiac fibrosis.Curr Opin Nephrol Hypertens，2004，13（2）：197-204.

94. Sodin-Semri S，Taddeo B，Tseng D，et al.Lipoxin A4 inhibits IL-1 beta-induced IL-6，IL-8，and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases.J Immunol，2000，164（5）：2660-2666.

95. Tagoe C E，Marjanovic N，Park J Y，et al.Annexin-1 mediates TNF-αlpha-stimulated matrix metalloproteinase secretion from rheumatoid arthritis synovial fibroblasts.J Immunol，2008，181（4）：2813-2820.

96. Zhou H Y，Hao J L，Bi M M，et al.Molecular mechanism of the inhibition effect of Lipoxin A4 on corneal dissolving pathology process.Int J Ophthalmol，2013，6（1）：39-43.

97. Yang Y C，Zhang N，Van Crombruggen K，et al.Transforming growth factor-beta1 in inflammatory airway disease：a key for understanding inflammation and remodeling.Allergy，2012，67（10）：1193-1202.

98. Han G，Li F，Singh T P，et al.The pro-inflammatory role of TGFbeta1：a paradox？.Int J Biol Sci，2012，8（2）：228-235.

99. Bowen T，Jenkins R H，Fraser D J.MicroRNAs，transforming growth factor beta-1，and tissue fibrosis.J Pathol，2013，229 （2）：274-285.